Meropenem administered as a prolonged infusion to treat serious gram-negative central nervous system infections

Pharmacotherapy

Volumn 24, Issue 6, 2004, Pages 803-807

  Capitano, Blair ^a,c   Nicolau, David P ^d   Potoski, Brian A ^a,c   Byers, Karin E ^a,b   Horowitz, Michael ^a,b   Venkataramanan, Raman ^c   Paterson, David L ^a,b,e  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d HARTFORD HOSPITAL   (United States)

^e Falk Medical Building ^*  (United States)

Author keywords

Antibiotic management; Antibiotic resistance; Central nervous system; Gram negative central nervous system infection; Meningitis; Meropenem; Pharmacodynamics; Pharmacokinetics

Indexed keywords

CEFEPIME; GENTAMICIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERICIDAL ACTIVITY; CASE REPORT; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID ANALYSIS; CONCENTRATION RESPONSE; DRUG MEGADOSE; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; REACTION OPTIMIZATION;

ADULT; CROSS INFECTION; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MENINGITIS, BACTERIAL; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; SERRATIA MARCESCENS; THIENAMYCINS; TIME FACTORS;

EID: 2942623605     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.8.803.36070     Document Type: Article

References (19)

1. Federico G, Tumbarello M, Spanu T, et al. Risk factors and prognostic indicators of bacterial meningitis in a cohort of 3580 postneurosurgical patients. Scand J Infect Dis 2001;33:533-7.
2. Klugman KP, Dagan R. Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis: meropenem meningitis study group. Antimicrob Agents Chemother 1995;39:1140-6.
3. Donnelly JP, Horrevorts AM, Sauerwein RW, De Pauw BE. High-dose meropenem in meningitis due to Pseudomonas aeruginosa [letter]. Lancet 1992;339:1117.
4. Chmelik V, Gutvirth J. Meropenem treatment of post-traumatic meningitis due to Pseudomonas aeruginosa. J Antimicrob Chemother 1993;32:922-3.
5. Dagan R, Velghe L, Rodda JL, Klugman KP. Penetration of meropenem into the cerebrospinal fluid of patients with inflamed meninges. J Antimicrob Chemother 1994;34:175-9.
6. Nau R, Lassek C, Kinzig-Schippers M, Thiel A, Prange HW, Sorgel F. Disposition and elimination of meropenem in cerebrospinal fluid of hydrocephalic patients with external ventriculostomy. Antimicrob Agents Chemother 1998;42:2012-16.
7. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-12.
8. Walker R, Andes D, Cinklin R, Ebert S, Craig WA. Pharmacodynamic activities of meropenem in an animal infection model [abstr]. In: Program and abstracts of the 34th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 1994.
9. Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis 1998;27:10-22.
10. Dandekar PK, Maglio D, Sutherland CA, Nightingale CH, Nicolau DP. Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion. Pharmacotherapy 2003;23:988-91.
11. Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin Pharmacol 2003;43:1116-23.
12. Elkhaili H, Niedergang S, Pompei D, Linger L, Leveque D, Jehl F. High-performance liquid chromatographic assay for meropenem in serum. J Chromatogr B-Biomed Sci Appl 1996;686:19-26.
13. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
14. Lomaestro BM, Drusano GL. Pharmacodynamic evaluation of extending the infusion time of meropenem compared to standard imipenem/cilastatin doses using Monte Carlo simulation [abstr]. In: Program and abstracts of the 42nd interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2002:A-636.
15. AstraZeneca Pharmaceuticals. Merrem (meropenem) product information. Wilmington, DE; 2001.
16. Tauber MG, Kunz S, Zak O, Sande MA. Influence of antibiotic dose, dosing interval, and duration of therapy on outcome in experimental pneumococcal meningitis in rabbits. Antimicrob Agents Chemother 1989;33:418-23.
17. Lutsar I, Ahmed A, Friedland IR, et al. Pharmacodynamics and bactericidal activity of ceftriaxone therapy in experimental cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1997;41:2414-17.
18. Lutsar I, McCracken GH Jr, Friedland IR. Antibiotic pharmacodynamics in cerebrospinal fluid. Clin Infect Dis 1998;27:1117-29.
19. Slavik RS, Jewesson PJ. Selecting antibacterials for outpatient parenteral antimicrobial therapy: pharmacokinetic-pharmacodynamic considerations. Clin Pharmacokinet 2003;42:793-817.